Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying women who carry mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 to better understand their risk of developing cancer. This observational study aims to collect national data from women with these mutations, as current management strategies are not fully established. The study focuses on the Italian population, where an estimated 140,000 to 150,000 women carry these mutations, and many face a high lifetime risk of genetically linked tumors. Participants will be registered on a platform where their clinical data related to BRCA1 or BRCA2 mutations will be collected. The study does not involve treatment but gathers detailed information about mutation distribution, access to genetic evaluation, lifestyle risk factors, preventive strategies, and surgical risk reduction approaches such as salpingo-oophorectomy. Women in the study will provide data that researchers will analyze to understand mutation geography, related cancer types, and screening criteria. Data collection occurs over different time frames, including immediate and six-month intervals. The study continues through long-term observation to monitor outcomes and preventive efforts, with no active intervention applied to participants.
Actively Recruiting
Aromatic L-amino acid decarboxylase deficiency AADC-D is a rare genetic condition that affects brain chemicals and can cause serious neurological and developmental issues in newborns. Early diagnosis is important to allow timely specialist care and evaluation for treatment options such as gene therapy. This study aims to develop a newborn screening program for AADC-D in the Liguria region of Italy and estimate how often the disease occurs in this population. The study will include about 16,000 newborns born in participating hospitals. After parents or legal caregivers give consent, blood samples will be collected using dried blood spot cards as part of the existing newborn screening routine. These samples will be tested with tandem mass spectrometry to measure 3-O-methyldopa 3-OMD, a marker that may indicate AADC-D. Samples with positive results will be retested, and if still positive, genetic testing of the DDC gene will confirm the diagnosis. Participants are involved only through the collection of blood samples during routine newborn screening. Researchers will evaluate 3-OMD levels, establish reference and cut-off values for screening, and assess the screening methods performance over two years. The study aims to support a reliable newborn screening program for early detection of AADC-D, enabling prompt identification and care of affected infants.